Acute promyelocytic leukaemia: novel insights into the mechanisms of cure

被引：370

作者：

de The, Hugues ^{[1
,2
,4
]}

Chen, Zhu ^{[3
,4
]}

机构：

[1] CNRS, INSERM, F-75475 Paris 10, France

[2] Univ Paris Diderot UMR 944 7212, Inst Univ Hematol, Hop St Louis, Equipe Labellisee Ligue Canc,Serv Biochim, F-75475 Paris 10, France

[3] Shanghai Jiao Tong Univ, State Key Lab Med Genom, Shanghai Inst Haematol, Rui Jin Hosp,Sch Med, Shanghai 200025, Peoples R China

[4] Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China

来源：

NATURE REVIEWS CANCER | 2010年 / 10卷 / 11期

基金：

中国国家自然科学基金;

关键词：

TRANS-RETINOIC ACID; PML-RAR-ALPHA; TUMOR-SELECTIVE APOPTOSIS; ARSENIC TRIOXIDE AS2O3; ACUTE MYELOID-LEUKEMIA; RECEPTOR-ALPHA; IN-VITRO; CELL-DIFFERENTIATION; HISTONE DEACETYLASE; NUCLEAR-BODIES;

D O I：

10.1038/nrc2943

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The fusion oncogene, promyelocytic leukaemia (PML)-retinoic acid receptor-alpha (RARA), initiates acute promyelocytic leukaemia (APL) through both a block to differentiation and increased self-renewal of leukaemic progenitor cells. The current standard of care is retinoic acid (RA) and chemotherapy, but arsenic trioxide also cures many patients with APL, and an RA plus arsenic trioxide combination cures most patients. This Review discusses the recent evidence that reveals surprising new insights into how RA and arsenic trioxide cure this leukaemia, by targeting PML-RAR alpha for degradation. Drug-triggered oncoprotein degradation may be a strategy that is applicable to many cancers.

引用

页码：775 / 783

页数：9

共 160 条

[1] Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations
Akagi, Tadayuki
Shih, Lee-Yung
Kato, Motohiro
Kawamata, Norihiko
Yamamoto, Go
Sanada, Masashi
Okamoto, Ryoko
Miller, Carl W.
Liang, Der-Cherng
Ogawa, Seishi
Koeffler, H. Phillip
[J]. BLOOD, 2009, 113 (08) : 1741 - 1748
[2] Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor
Altucci, L
Rossin, A
Hirsch, O
Nebbioso, A
Vitoux, D
Wilhelm, E
Guidez, F
De Simone, M
Schiavone, EM
Grimwade, D
Zelent, A
de Thé, H
Gronemeyer, H
[J]. CANCER RESEARCH, 2005, 65 (19) : 8754 - 8765
[3] [Anonymous], 2010, Frontiers of Medicine in China
[4] RAR-independent RXR signaling induces t(15;17) leukemia cell maturation
Benoit, G
Altucci, L
Flexor, M
Ruchaud, S
Lillehaug, J
Raffelsberger, W
Gronemeyer, H
Lanotte, M
[J]. EMBO JOURNAL, 1999, 18 (24) : 7011 - 7018
[5] Regulation of apoptosis by PML and the PML-NBs
Bernardi, R.
Papa, A.
Pandolfi, P. P.
[J]. ONCOGENE, 2008, 27 (48) : 6299 - 6312
[6] Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies
Bernardi, Rosa
Pandolfi, Pier Paolo
[J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2007, 8 (12) : 1006 - 1016
[7] MOLECULAR ANALYSIS OF ACUTE PROMYELOCYTIC LEUKEMIA BREAKPOINT CLUSTER REGION ON CHROMOSOME-17
BORROW, J
GODDARD, AD
SHEER, D
SOLOMON, E
[J]. SCIENCE, 1990, 249 (4976) : 1577 - 1580
[8] The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation
Boukarabila, Hanane
Saurin, Andrew J.
Batsche, Eric
Mossadegh, Noushine
van Lohuizen, Maarten
Otte, Arie P.
Pradel, Jacques
Muchardt, Christian
Sieweke, Michael
Duprez, Estelle
[J]. GENES & DEVELOPMENT, 2009, 23 (10) : 1195 - 1206
[9] Breitman T R, 1981, Blood, V57, P1000
[10] A PMLRAR alpha transgene initiates murine acute promyelocytic leukemia
Brown, D
Kogan, S
Lagasse, E
Weissman, I
Alcalay, M
Pelicci, PG
Atwater, S
Bishop, JM
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) : 2551 - 2556

← 1 2 3 4 5 6 7 8 9 10 →